Efficiency and prognosis of hematological malignancies with different tumor burden treated by haploidentical hematopoietic stem cell transplantation
10.3760/cma.j.issn.1009-9921.2014.07.011
- VernacularTitle:单倍型造血干细胞移植治疗不同肿瘤负荷恶性血液病的效果及预后分析
- Author:
Rongmu LUO
;
Xiaomei ZHANG
;
Zhenlan DU
;
Quanhua LIU
;
Ya WANG
;
Wanming DA
- Publication Type:Journal Article
- Keywords:
Hematopoietic neoplasms;
Haploidentical;
Hematopoietic stem cell transplantation;
Relapse;
Tumor burden
- From:
Journal of Leukemia & Lymphoma
2014;23(7):420-423
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficiency and prognosis of hematological malignancies treated by haploidentical hematopoietic stem cell transplantation.Methods 70 patients who received haploidentical hematopoietic stem cell transplantation were analyzed retrospectively.According to tumor burden before transplantation,the patients were divided into three groups,the low tumor burden group,the mediate tumor burden group and the high tumor burden group.And then the effection of the tumor burden to survival was analyzed,and the engraftment,GVHD,infection,conditioning related toxicity,relapse and survival rate were also observed.Results The follow-up was terminated on January 1,2014.Follow-ups were performed for a median of 34.05 (7.4-83.6) months after transplantation.All patients achieved engraftments.The cumulative incidence of GVHD of grades 2-4 was 47.14 ％ (33/70) and that of grades 3-4 was 21.4 ％ (15/70).The chronic extensive GVHD was 20.0 ％ (14/70).The overall survival was 68.6 ％.Transplant-related mortality was 12.8 ％ and the relapse was 18.6 ％.The overall survivals in low tumor burden group,mediate tumor burden group,high tumor burden group were 91.67 ％,72.7 ％,33.3 ％ respectively.By SPSS 20.0,tumor burden was the high risk factor affecting the survival (low tumor group vs high tumor group,mediate tumor group vs high tumor group,low tumor group vs high tumor group,P =0.000,P =0.038,P =0.016).Conclusions Haploidentical hematopoietic stem cell transplantation in hematological malignancies is safe and effective.And for hematological malignancies with poor prognosis disease,it should be accepted the HSCT as soon as possible after remission in order to reduce the recurrence rate of malignancy.
